1. Scrip

BMS Gets US Approval Of Ozanimod For Relapsing MS, But Launch Delayed

 
• By Joseph Haas

Zeposia, one of three Celgene candidates central to last year’s merger with BMS, obtains US FDA approval in relapsing MS. BMS, however, will delay the launch due to the COVID-19 pandemic.

3d illustration of nerve cells, concept for Neurological Diseases, tumors and brain surgery.
BMS says Zeposia offers a new treatment option for relapsing MS patients

It’s one down and two to go both for Bristol-Myers Squibb Co. and for shareholders in the former Celgene Corp. as ozanimod obtained US Food and Drug Administration approval for relapsing multiple sclerosis on 26 March, about two years after the FDA issued a “refuse-to-file” letter for the drug citing insufficient clinical and non-clinical pharmacology data in the new drug application.

Ozanimod, to be branded Zeposia, was cited as one of three primary Celgene pipeline assets driving last year’s $74bn buyout,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

Bluebird Builds Out Leadership Team Under Private Equity Ownership

 
• By Jessica Merrill

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.